Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin in indolent or smoldering systemic mastocytosis
2012-004868-22Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in indolent systemic mastocytosis (ISM) and systemic mastocytosis (SM), sponsored by University Medical Center Groningen. Primary endpoint: Percent change in total symptom score at 12 weeks. Started Jul 2013; status: active.
02
Drugs
midostaurin
03
Conditions
indolent systemic mastocytosis (ISM)systemic mastocytosis (SM)
Beyond the preview
Go deeper on 2012-004868-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004868-22.